Studies correlating PDX treatment results with clinical data
Tumor type (reference) | Definition activity | Standard agent | n | RR (%) | Clinical correlates |
---|---|---|---|---|---|
CRC | TR > 50% | Cetuximab | 47 | 10 | N/A |
CRC KRAS WT (28) | Cetuximab | 38 | 17 | ||
CRC (29) | T/C < 10% | 5-Fluorouracil | 52 | 13 | N/A |
Oxaliplatin | 52 | 0 | |||
Irinotecan | 49 | 38 | |||
Cetuximab | 52 | 26 | |||
HBC (34) | Complete response | AC | 17 | 76 | Response to treatment in the PDX model was concordant with clinical data in 5/7 patients. |
TGI > 50% or T/C GD > 2-fold | Docetaxel | 17 | 47 | ||
Trastuzumab | 2 | 50 | |||
GnRH antagonist | 1 | 100 | |||
HBC (16) | RR > 30% | Docetaxel | 7 | 14 | 92% correlation between clinical responses and responses in PDX |
Doxorubicin | 4 | 0 | |||
Trastuzumab–lapatinib | 1 | 100 | |||
NSCLC (20) | Statistically significant decrement in tumor area in treated vs. control tumors | Cisplatin–vinorelbine | 32 | 28 | PDX models from 6/7 patients with early recurrent disease were resistant to the clinically used regimen. |
Cisplatin–docetaxel | 19 | 42 | |||
Cisplatin–gemcitabine | 16 | 44 | |||
NSCLC (21) | T/C < 5% | Etoposide | 25 | 4 | N/A |
Carboplatin | 25 | 12 | |||
Gemcitabine | 25 | 12 | |||
Paclitaxel | 25 | 16 | |||
Vinorelbine | 11 | 0 | |||
Cetuximab | 25 | 12 | |||
Erlotinib | 25 | 1 | |||
SCCHN (25) | T/C < 20% | Cetuximab | 11 | 9% | N/A |
RCC (15) | Statistically significant differences in TGI | Sunitinib | 8 | Active | N/A |
Sirolimus | Active | ||||
Erlotinib | Inactive | ||||
PDAC (26) | T/C < 20% | Gemcitabine | 14 | 36 | N/A |
Erlotinib | 0 | ||||
Temsirolimus | 0 | ||||
PDAC (33) | TGI > 85% | Gemcitabine | 23 | 17% | Response to gemcitabine in the PDX model predicted longer time to progression in patients. |
NOTE: This table provides a summary of studies in which PDX models from different cancer types have been treated with agents used in the clinical care of these patients.
Abbreviations: AC, adriamycin–cyclophosphamide; CRC, colorectal cancer; GD, growth delay; GnRH, gonadotrophin-releasing hormone; HBC, human breast cancer; N/A, not available; RR, response rate; TGI, tumor growth inhibition; TR, tumor regression; T/C, treated divided by control; WT, wild-type.